PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that is upregulated on activated T cells for the induction of immune tolerance. Tumour cells frequently overexpress the ligand for PD-1, programmed cell death ligand 1 (PD-L1), facilitating their escape from the immune system. Monoclonal antibodies that block the interaction between PD-1 and PD-L1, by binding to either the ligand or receptor, have shown notable clinical efficacy in patients with a variety of cancers, including melanoma, colorectal cancer, non-small-cell lung cancer and Hodgkin's lymphoma. Although it is well established that PD-1-PD-L1 blockade activates T cells, little is known about the role that this pathway may have in tumour-associated macrophages (TAMs). Here we show that both mouse and human TAMs express PD-1. TAM PD-1 expression increases over time in mouse models of cancer and with increasing disease stage in primary human cancers. TAM PD-1 expression correlates negatively with phagocytic potency against tumour cells, and blockade of PD-1-PD-L1 in vivo increases macrophage phagocytosis, reduces tumour growth and lengthens the survival of mice in mouse models of cancer in a macrophage-dependent fashion. This suggests that PD-1-PD-L1 therapies may also function through a direct effect on macrophages, with substantial implications for the treatment of cancer with these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and treatment with checkpoint inhibitors targeting PD-1 or PD-L1 increases phagocytosis and reduces tumor growth [329].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [329]
In the citing paper
“In human and mouse CRC tumor models, high levels of PD-1 expression on TAM have low tumor phagocytosis”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [329]
In the citing paper
“Tumor-associated macrophages were also recently shown to express PD-1 in both mice and humans with colorectal cancer and to impair macrophage phagocytosis (59).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Cited by
Items 701–800 of 1,001
Cheng, B., Lv, J., Xiao, Y., Song, C., Chen, J., & Shao, C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117141 · Cited by 41
Immunotherapeutic strategies in head and neck cancer: challenges and opportunities
Liu, X., Harbison, R. A., Varvares, M. A., Puram, S. V., & Peng, G. (2025) · Journal of Clinical Investigation · doi:10.1172/jci188128 · Cited by 45
Nonresolving macrophage‐mediated inflammation in malignancy
Murray, P. J. (2017) · FEBS Journal · doi:10.1111/febs.14210 · Cited by 40
Mills, A. M., Peres, L. C., Meiss, A. E., Ring, K. L., Modesitt, S. C., Abbott, S. E., Alberg, A. J., Bandera, E. V., Barnholtz‐Sloan, J. S., Bondy, M. L., et al. (2018) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000494 · Cited by 40
Matsuo, N., Azuma, K., Hattori, S., Ohtake, J., Kawahara, A., Ishii, H., Tokito, T., Yamada, K., Shibata, Y., Shimokawaji, T., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31923 · Cited by 42
Gómez‐Abenza, E., Ibáñez‐Molero, S., García‐Moreno, D., Fuentes, I., Zon, L. I., Mione, M., Cayuela, M. L., Gabellini, C., & Mulero, V. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1389-3 · Cited by 38
Searching for the real function of mTOR signaling in the regulation of PD-L1 expression
Sun, S. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100847 · Cited by 45
Tartey, S., Neale, G. A. M., Vogel, P., Malireddi, R. K. S., & Kanneganti, T. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3510 · Cited by 40
Lawal, B., Lin, L.-C., Lee, J., Chen, J.-H., Bekaii‐Saab, T., Wu, A. T. H., & Ho, C. (2021) · Cancers · doi:10.3390/cancers13050954 · Cited by 41
Yu, T., Nie, W., Hong, Z., He, Y., Chen, J., Mi, X., Yang, S., Li, X., Wang, B., Lin, Y., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100715 · Cited by 38
Han, S., Wang, P., Cai, H., Wan, J., Li, S., Lin, Z.-H., Yu, C., & Yan, C. (2021) · Aging · doi:10.18632/aging.203102 · Cited by 38
Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
Yang, Y., Yang, Z., & Yang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686031 · Cited by 43
Wu, R., Zhou, T., Xiong, J., Zhang, Z., Tian, S., Wang, Y., Chen, J., & Tian, X. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2712323 · Cited by 40
Immune checkpoint inhibitors and reproductive failures
Chen, Z., Huang, J., Kwak-Kim, J. Y.-H., & Wang, W. (2023) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2023.103799 · Cited by 38
Hu, Z., Li, W., Chen, S., Chen, D., Xu, R., Zheng, D., Yang, X., Li, S., Zhou, X., Niu, X., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-022-2285-6 · Cited by 39
Shen, S., Zhang, Z., Huang, H., Yang, J., Tao, X., Meng, Z., Ren, H., & Li, X. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00389-4 · Cited by 41
Ge, Y., Zhang, J., Jin, K., Ye, Z., Wang, W., Zhou, Z., & Ye, J. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.05.051 · Cited by 39
Zhao, S., Wang, Q., Ni, K., Zhang, P., Liu, Y., Xie, J., Ji, W., Cheng, C., & Zhou, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1263329 · Cited by 50
Effects of PD-1 Signaling on Immunometabolic Reprogramming
Boussiotis, V. A., & Patsoukis, N. (2022) · Immunometabolism · doi:10.20900/immunometab20220007 · Cited by 41
Steenbrugge, J., Bellemans, J., Elst, N. V., Demeyere, K., Vliegher, J. D., Perera, T. P. S., Wever, O. D., Broeck, W. V. D., Spiegelaere, W. D., Sanders, N. N., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2103277 · Cited by 39
Wang, P., Sun, L., Li, C., Jin, B., Yang, H., Wu, B., & Mao, Y. (2023) · International Journal of Bioprinting · doi:10.18063/ijb.694 · Cited by 38
PD-1/PD-L1 axis in organ fibrosis
Zhao, Y., Qu, Y., Hao, C., & Yao, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1145682 · Cited by 48
Chen, Y., Zhou, J., Liu, Z., Wu, T., Li, S., Zhang, Y., Yin, X., Yang, G., & Zhang, G. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02856-1 · Cited by 39
Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade
Wang, C., Chen, L., Fu, D., Liu, W., Puri, A., Kellis, M., & Yang, J. (2024) · Clinical & Experimental Metastasis · doi:10.1007/s10585-023-10257-z · Cited by 39
Liu, D., Liu, L., Zhao, X., Zhang, X., Chen, X., Che, X., & Wu, G. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104702 · Cited by 43
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma
Stahl, D. J., Gödel, P., Balke‐Want, H., Gholamipoorfard, R., Segbers, P., Tetenborg, L., Koker, M., Dörr, J., Gregor, L., Bachurski, D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.013 · Cited by 44
Zhang, X., Chen, C., Hou, J., Qi, X., Wang, X., Han, P., & Yang, X. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0021-3 · Cited by 39
Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer
Guan, W., Hu, J., Yang, L., Tan, P., Tang, Z., West, B. L., Bollag, G. E., Xu, H., & Wu, L. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0284 · Cited by 39
Biohybrid Nanoparticles to Negotiate with Biological Barriers
Mohammadi, M. R., Corbo, C., Molinaro, R., & Lakey, J. R. T. (2019) · Small · doi:10.1002/smll.201902333 · Cited by 38
Lai, B., Wang, J., Fagenson, A. M., Sun, Y., Saredy, J., Lu, Y., Nanayakkara, G., Yang, W. Y., Yu, D., Shao, Y., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02612 · Cited by 41
Evrard, D., Hourseau, M., Couvelard, A., Paradis, V., Gauthier, H., Raymond, É., Halimi, C., Barry, B., & Faivre, S. J. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1844403 · Cited by 41
Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers
Hwang, K., Yoon, J. H., Lee, J., & Lee, S. (2021) · Biomedicines · doi:10.3390/biomedicines9010039 · Cited by 40
Zhou, J., Pei, X., Yang, Y.-G., Wang, Z., Gao, W., Ye, R., Zhang, X., Liu, J., Liu, Z., Yang, X., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001937 · Cited by 40
Testicular Diffuse Large B-Cell Lymphoma—Clinical, Molecular, and Immunological Features
Pollari, M., Leivonen, S., & Leppä, S. (2021) · Cancers · doi:10.3390/cancers13164049 · Cited by 39
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 39
PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
Li, J., Peng, G., Zhu, K., Jie, X., Xu, Y., Rao, X., Xu, Y., Chen, Y., Xing, B., Wu, G., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03282-6 · Cited by 39
Advances in landscape and related therapeutic targets of the prostate tumor microenvironment
Li, D., Xu, W., Chang, Y. E., Xiao, Y., He, Y., & Ren, S. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023092 · Cited by 39
Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes
Gonçalves, L., Gonçalves, D., Esteban-Casanelles, T., Barroso, T., de Pinho, I. S., Lopes-Brás, R., Esperança‐Martins, M., Patel, V., Torres, S., Sousa, R., et al. (2023) · Cells · doi:10.3390/cells12162068 · Cited by 38
Glucocorticoids mobilize macrophages by transcriptionally up-regulating the exopeptidase DPP4
Diaz-Jimenez, D., Petrillo, M. G., Busada, J. T., Hermoso, M. A., & Cidlowski, J. A. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010894 · Cited by 37
“Thus, macrophages may contribute to the pathophysiology of several diseases, including inflammatory disorders (20, 21), cancer (22), and also states of low-grade inflammation such as obesity (23, 24).”
BackgroundDiaz, L., Jauzelon, B., Dilies, A. C., Souder, C. L., Faillie, J., Maria, A. T. J., & Palassin, P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051985 · Cited by 36
Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy
Liu, S., Wang, H., Shao, X., Chen, H., Chao, S., Zhang, Y., Gao, Z., Yao, Q., & Zhang, P. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01966-4 · Cited by 40
Macrophage-specific in vivo RNA editing promotes phagocytosis and antitumor immunity in mice
Chen, Y., Chen, X., Zhang, Y., Wang, M., Yang, M., Wang, R. Y., Yan, X., Shao, S., Xin, H., Hu, Q., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adl5800 · Cited by 40
Harnessing chimeric antigen receptor macrophages against solid tumors
Wang, M., Qin, Z., Bian, X., & Shi, Y. (2025) · 癌症:英文版 · doi:10.1002/cac2.70053 · Cited by 38
Tumor-associated macrophages in cancer: from mechanisms to application
Tang, W., Wang, X., Han, B., Jiang, S.-H., & Cao, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00396-y · Cited by 47
Stromal PD-1+ tumor-associated macrophages predict poor prognosis in lung adenocarcinoma
Chen, L., Cao, M., Xiao, J., Ma, Q., Zhang, H., Cai, R., Miao, J., Wang, W.-Y., Zhang, H., Luo, M., et al. (2020) · Human Pathology · doi:10.1016/j.humpath.2019.12.007 · Cited by 36
Shu, C., & Li, Q. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102965 · Cited by 41
Lacal, P. M., Atzori, M. G., Ruffini, F., Scimeca, M., Bonanno, E., Cicconi, R., Mattei, M., Bernardini, R., D’Atri, S., Tentori, L., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104957 · Cited by 39
Jiménez, I., Carabia, J., Bobillo, S., Palacio, C., Abrisqueta, P., Pagès, C., Nieto, J. C., Castellví, J., Ricarte, F. M., Escoda, L., et al. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03580-y · Cited by 41
Deng, L., He, K., Pan, Y., Wang, H., Luo, Y., & Xia, Q. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.56003 · Cited by 40
Li, X., Yang, Y., Huang, Q., Deng, Y., Guo, F., Wang, G., & Liu, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.738373 · Cited by 39
Greenberg, J. W., Kim, H., Ahn, M., Moustafa, A. A., Zhou, H., Barata, P. C., Boulares, A. H., Abdel‐Mageed, A. B., & Krane, L. S. (2022) · Cancers · doi:10.3390/cancers14040903 · Cited by 39
Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer
Chen, Y., Bai, B., Ying, K., Pan, H., & Xie, B. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188775 · Cited by 42
Lucarini, V., Melaiu, O., D’Amico, S., Pastorino, F., Tempora, P., Scarsella, M., Pezzullo, M., Ninno, A. D., Doria, V., Cilli, M., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02525-9 · Cited by 38
Han, J., Dong, L., Wu, M., & Ma, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160340 · Cited by 39
Tumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs
Brady, R. V., & Thamm, D. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1176807 · Cited by 35
Microglia–T cell conversations in brain cancer progression
Mirzaei, R., & Yong, V. W. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.08.006 · Cited by 37
Tumor-associated macrophages as a potential therapeutic target in thyroid cancers
Zhu, L., Li, X. J., Gangadaran, P., Jing, X., & Ahn, B. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03549-6 · Cited by 39
Guo, Y., Cui, J. R., Liang, X., Chen, T., Lu, C., & Peng, T. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111407 · Cited by 39
Meci, A., Goyal, N., & Slonimsky, G. (2024) · Cancers · doi:10.3390/cancers16040703 · Cited by 39
Liu, J., Song, K., Lin, B., Chen, Z., Zuo, Z., Fang, Y., He, Q., Yao, X., Liu, Z., Huang, Q., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112130 · Cited by 38
Li, Z., Duan, D., Li, L., Peng, D., Ming, Y., Ni, R., & Liu, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1382256 · Cited by 44
Soluble PD-L1 improved direct ARDS by reducing monocyte-derived macrophages
Xu, J., Wang, J., Wang, X., Tan, R., Qi, X., Liu, Z., Qu, H., Pan, T., Zhan, Q., Zuo, Y., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03139-9 · Cited by 35
E3 ligase FBXW7 restricts M2-like tumor-associated macrophage polarization by targeting c-Myc
Zhong, L., Zhang, Y., Li, M., Song, Y., Liu, D., Yang, X., Yang, D., Qu, H., Lai, L., Wang, Q., et al. (2020) · Aging · doi:10.18632/aging.202293 · Cited by 37
Soyama, T., Sakuragi, A., Oishi, D., Kimura, Y., Aoki, H., Nomoto, A., Yano, S., Nishie, H., Kataoka, H., & Aoyama, M. (2021) · Translational Oncology · doi:10.1016/j.tranon.2020.101005 · Cited by 36
Bao, J., Zhang, Q., Duan, T., Hu, R., & Tang, J. (2021) · Current Drug Targets · doi:10.2174/1389450122666210118105122 · Cited by 38
Yang, X., Lam, W., Jiang, Z., Guan, F., Han, X. N., Hu, R., Cai, W., Cheng, W., Liu, S.-H., Cheng, P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91623-3 · Cited by 35
Greco, L., Rubbino, F., Buono, A. D., & Laghi, L. (2023) · Genes · doi:10.3390/genes14061169 · Cited by 42
Chen, J., Duan, Z., Deng, L., Li, L., Li, Q., Qu, J., Li, X., & Liu, R. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304436 · Cited by 39
Zhou, X., Yan, Z., Hou, J., Zhang, L., Chen, Z., Gao, C., Ahmad, N. H., Guo, M., Wang, W., Han, T., et al. (2024) · Oncogene · doi:10.1038/s41388-023-02923-z · Cited by 38
LAG‐3 : recent developments in combinational therapies in cancer
Chavanton, A., Mialhe, F., Abrey, J., Garcia, A. B., & Garrido, C. (2024) · Cancer Science · doi:10.1111/cas.16205 · Cited by 38
Li, Z., Jiang, S., Wang, J., Li, W., Yang, J., Liu, W., Gao, H., Huang, Y., & Ruan, S. (2025) · Science Advances · doi:10.1126/sciadv.adr8841 · Cited by 35
Chen, W., Jiang, M., Zou, X., Chen, Z., Shen, L., Hu, J., Kong, M., Huang, J., Ni, C., & Xia, W. (2025) · Oncogene · doi:10.1038/s41388-025-03359-3 · Cited by 41
Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms
Sun, L., Chen, L., & Li, H. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.12.006 · Cited by 36
Takkenkamp, T. J., Jalving, M., Hoogwater, F. J. H., & Walenkamp, A. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0113 · Cited by 37
Gelsomino, L., Naimo, G. D., Malivindi, R., Augimeri, G., Panza, S., Giordano, C., Barone, I., Bonofiglio, D., Mauro, L., Catalano, S., et al. (2020) · Cancers · doi:10.3390/cancers12082078 · Cited by 34
Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment
Koo, J., Hayashi, M., Verneris, M. R., & Lee‐Sherick, A. B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.581107 · Cited by 39
Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application
Miyashita, M., Shimizu, T., Ashihara, E., & Ukimura, O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168910 · Cited by 36
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
Liu, H.-T., Jiang, M., Deng, Z., Li, L., Huang, J.-L., Liu, Z., Li, L., & Zhong, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.737497 · Cited by 40
Macrophage-associated immune checkpoint CD47 blocking ameliorates endometriosis
Li, J., Yan, S., Li, Q., Huang, Y., Ji, M., Jiao, X., Yuan, M., & Wang, G. (2022) · Molecular Human Reproduction · doi:10.1093/molehr/gaac010 · Cited by 37
Dai, X., Li, X., Liu, Y., & Yan, F. (2022) · Materials & Design · doi:10.1016/j.matdes.2022.110656 · Cited by 34
Wu, Z., Lei, K., Li, H., He, J., & Shi, E. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03686-z · Cited by 35
Wang, K., Cai, R., Fei, S., Chen, X., Feng, S., Zhang, L., Liu, H., Zhang, Z., Song, J. W., & Zhou, R. (2023) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2023.111917 · Cited by 34
McCune, J. M., & Weissman, I. L. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.10.003 · Cited by 35
Self-citationContribution of Macrophages and T Cells in Skeletal Metastasis
Mendoza‐Reinoso, V., McCauley, L. K., & Fournier, P. G. J. (2020) · Cancers · doi:10.3390/cancers12041014 · Cited by 37
Gut microbiota: A double-edged sword in immune checkpoint blockade immunotherapy against tumors
Wang, J., Zhu, N., Su, L., & Yang, R. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216582 · Cited by 37
Bioengineering extracellular vesicle cargo for optimal therapeutic efficiency
René, C. A., & Parks, R. J. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101259 · Cited by 38
Liu, R., Li, J., Liu, L., Wang, W., & Jia, J. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.07.004 · Cited by 39
Chen, K., Li, X., Dong, S., Guo, Y., Luo, Z., Zhuang, S., Liu, J., Liu, T., Liao, J., & Wen, W. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-06036-3 · Cited by 41
Fujimura, T., Sato, Y., Tanita, K., Kambayashi, Y., Otsuka, A., Fujisawa, Y., Yoshino, K., Matsushita, S., Funakoshi, T., Hata, H., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00530 · Cited by 34
Yang, Z., Xu, J., Li, R., Gao, Y., & He, J. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03023-w · Cited by 36
Clinical Relevance of CD4 Cytotoxic T Cells in High-Risk Neuroblastoma
Tang, X. X., Shimada, H., & Ikegaki, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.650427 · Cited by 35
Old Stars and New Players in the Brain Tumor Microenvironment
Parmigiani, E., Scalera, M., Mori, E., Tantillo, E., & Vannini, E. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.709917 · Cited by 35
Noncoding RNA-mediated macrophage and cancer cell crosstalk in hepatocellular carcinoma
Zhou, Z., Wang, Z., Gao, J., Lin, Z., Wang, Y., Shan, P., Li, M., Zhou, T., & Li, P. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.03.002 · Cited by 37
The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?
Jiang, A., Liu, N., Wang, J., Zheng, X., Ren, M., Zhang, W., & Yao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1022228 · Cited by 34
Discovering Macrophage Functions Using In Vivo Optical Imaging Techniques
Li, Y., & Liu, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00502 · Cited by 38
Wang, C., Li, Y., Chen, H., Huang, K., Liu, X., Qiu, M., Liu, Y., Yang, Y., & Yang, J. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.247130 · Cited by 37
Next Generation Cancer Vaccines—Make It Personal!
Terbuch, A., & Lopez, J. S. (2018) · Vaccines · doi:10.3390/vaccines6030052 · Cited by 37
Picket-fences in the plasma membrane: functions in immune cells and phagocytosis
Mylvaganam, S., Grinstein, S., & Freeman, S. A. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0705-x · Cited by 37
Ahirwar, D. K., Peng, B., Charan, M., Misri, S., Mishra, S., Kaul, K., Sassi, S. E., Gadepalli, V. S., Siddiqui, J., Miles, W. O., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13289 · Cited by 32
Liu, Y., Xue, R., Duan, X., Shang, X., Wang, M., Wang, F., Zhu, L., Zhang, L., Ge, X., Zhao, X., et al. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121790 · Cited by 34
Metadata
- Authors
- Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., Ring, A. M., Connolly, A. J., & Weissman, I. L.
- Affiliations
- Stanford Medicine (US)
- Institute for Stem Cell Biology and Regenerative Medicine (US)
- Yale University (US)
- Corresponding author
- Weissman, Irving L.
- ORCID
- Venue
- Nature
- Published
- 2017-05
- Volume
- 545
- Issue
- 7655
- Pages
- 495-499
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5931375
- OpenAlex
- W2615301036
- Cited by
- 2,247
- References
- 34
- Citations by year
- 2026: 167 · 2025: 261 · 2024: 303 · 2023: 298 · 2022: 309 · 2021: 299 · 2020: 264 · 2019: 158 · 2018: 135 · 2017: 51
- FWCI
- 75.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Science Foundation
- Cancer Research Institute
- A.P. Giannini Foundation
- Giannini Foundation of Agricultural Economics
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (155336)
- National Institutes of Health (1s10rr026780-01)
- National Cancer Institute (R01CA086017, P30CA124435)
- National Institute of General Medical Sciences (T32GM007365)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32AR050942)
- National Center for Research Resources (1S10RR02678001, 1S10RR026780, S10 RR026780)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- PD-1, tumour-associated macrophages, PD-L1, phagocytosis, immune checkpoint blockade, tumour immunity, cancer immunotherapy, tumour-infiltrating macrophages
- MeSH terms
- Animals, Colonic Neoplasms, Disease Models, Animal, Female, Humans, Macrophages, Male, Mice, Inbred BALB C, Neoplasm Staging, Phagocytosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.